Curative Biotechnology, Inc. announced that Lawrence S. Zaslow has joined its Board of Directors as an independent director and will chair its Compensation Committee. Mr. Zaslow co-founded BioTheryX, Inc, a leader in protein degradation technology, along with three Celgene scientists, including David Stirling, co-founder of Celgene. In addition to being a founder, Mr. Zaslow also served as a director and president, over a period of fifteen years.

During his tenure at BioTheryX Mr. Zaslow had primary responsibility for: Strategic and operational planning Capital raising, financial planning/budget, corporate and business development, negotiation of licensing deals Investor relations and public relations. Mr. Zaslow helped position BioTheryX for its recent $100 million crossover round of financing and assembled a world class Scientific Advisory Board, including a Nobel Laureate. Prior to founding BioTheryX, Mr. Zaslow was a founding managing director of Amphion PLC, engaged in the formation, financing, management and development of life science and technology companies working in partnership with corporations, governments, universities and entrepreneurs seeking to commercialize their intellectual property.

Mr. Zaslow earned his BA in Economics from Brandeis University, and his MBA in Finance from the Columbia Business School.